157 related articles for article (PubMed ID: 37632452)
1. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
Maeda T; Moriwaki K; Morimoto K; Mo X; Yoshioka T; Goto R; Shimozuma K
Value Health Reg Issues; 2024 Mar; 40():118-126. PubMed ID: 38194896
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
8. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A; Besiroglu B; Adams A; Monsef I; Piechotta V; Tomlinson E; Hornbach C; Dressen N; Goldkuhle M; Maisch P; Dahm P; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2023 May; 5(5):CD013798. PubMed ID: 37146227
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
[TBL] [Abstract][Full Text] [Related]
10. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
[TBL] [Abstract][Full Text] [Related]
11. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067.
Baker T; Johnson H; Kotapati S; Moshyk A; Hamilton M; Kurt M; Paly VF
Pharmacoecon Open; 2022 Sep; 6(5):697-710. PubMed ID: 36006606
[TBL] [Abstract][Full Text] [Related]
17. First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.
Monteiro FSM; Soares A; Debiasi M; Schutz FA; Maluf FC; Bastos DA; Sasse A; Cauduro CGS; Mendes GO; Ziegelmann PK; Fay AP
Clin Genitourin Cancer; 2020 Aug; 18(4):244-251.e4. PubMed ID: 32303427
[TBL] [Abstract][Full Text] [Related]
18. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
20. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
